|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
Among the patients without overt CMD or thrombophilia and with unprovoked thrombosis, 29.4% (95% CI 16.8-46.1) with splanchnic venous thrombosis and 42.8% (95% CI 24.4-63.4) with PVT had the JAK2 V617F mutation.
|
17263783 |
2007 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
Thrombophilia abnormalities were significantly more prevalent in the MPN-CVT and MPN-VT than in MPN-NoT group (P = 0.015), as well as the JAK2 V617F mutation in patients with essential thrombocythemia (P = 0.059).
|
25042466 |
2014 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
In conclusion, in the younger patients with ET the thrombotic risk is higher in the JAK2 V617F-mutated and is further increased by the presence of inherited thrombophilia.
|
19336736 |
2009 |
|
Thrombophilia
|
|
0.080 |
GeneticVariation
|
BEFREE |
Nonetheless, we found a hypercoagulable state in Ph-CMPD with V617F by employing whole blood thromboelastography.
|
18612778 |
2008 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Given their diagnostic relevance, it is also beneficial and relatively straightforward to screen JAK2 V617F negative patients for JAK2 exon 12 mutations (in the case of erythrocytosis) or MPL exon 10 mutations (thrombocytosis or myelofibrosis) using appropriate assays.
|
23057517 |
2013 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The V617F JAK2 mutation was absent within the patients with secondary erythrocytosis or thrombocytosis.
|
19939582 |
2011 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
A 66-year-old man who presented with progressive and marked thrombocytosis but normal hemoglobin was diagnosed to have essential thrombocythemia upon the demonstration of JAK2 V617F mutation.
|
20633767 |
2010 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Ph+ chronic myelogenous leukemia (four cases), reactive (secondary) erythrocytosis (14 cases), and thrombocytosis (one case) as well as normal controls (19 cases) all lacked the V617F mutation.
|
16825501 |
2006 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Refractory anemia with ringed sideroblasts and thrombocytosis without JAK2 V617F mutation: report of three cases.
|
24399021 |
2013 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Time free from cytoreduction was significantly shorter in CALR-mutated patients with essential thrombocythemia than in JAK2(V617F)-mutated ones (median time 5 years and 9.8 years, respectively; P=0.0002) and cytoreduction was usually necessary to control extreme thrombocytosis.
|
27175028 |
2016 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The lack of thrombocytosis suggests that additional events may be required for JAK2 V617F to cause ET, but qualitative platelet abnormalities induced by JAK2 V617F may contribute to the hemostatic complications of PV.
|
17183644 |
2006 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The remaining cases usually lack the JAK2(V617F)mutation, have a platelet count less than 600 × 10(3)/μL (600 × 10(9)/L), and may represent an MDS or MPN with thrombocytosis of unknown mechanisms.
|
21350094 |
2011 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In all of them (in 3 with JAK2 V617F mutation and 1 with CALR mutation), thrombocytosis was present at the time when complete cytogenetic response was documented.
|
29508552 |
2018 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis.
|
20194893 |
2010 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis.
|
23594705 |
2013 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
In light of the findings from previous reports, screening for the JAK2-V617F mutation should be considered for any Ph(+) CML patients with thrombocytosis, leukocytosis, or erythrocytosis at diagnosis and for patients who subsequently develop thrombocytosis, leukocytosis, or erythrocytosis during follow-up, even for CML patients in complete cytogenetic response and major molecular response.
|
23613267 |
2013 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Thrombocytosis and STAT5 activation in CML-T are not consistently associated with CALR exon 9 or JAK2 V617F mutation.
|
26754830 |
2016 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
No association to thrombocytosis, JAK2(V617F) mutations or cytoreductive treatment (bone marrow cells) were observed.
|
18773208 |
2009 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
These data also support the hypothesis that level of JAK2(V617F) expression influences the MPN phenotype: higher levels favor erythrocytosis whereas lower levels favor thrombocytosis.
|
21242185 |
2011 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
We show that transplantation of JAK2(V617F)-transduced bone marrow into BALB/c mice induces MPD reminiscent of human PV, characterized by erythrocytosis, granulocytosis, extramedullary hematopoiesis, and bone marrow fibrosis, but not thrombocytosis.
|
17145859 |
2006 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Further investigations for intracoronary thrombus with no underlying atherosclerotic disease revealed positive Janus kinase 2 (JAK2) V617F gene mutation, and this was consistent with a diagnosis of ET with elevated platelet count.
|
22686448 |
2012 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
Higher levels of JAK2-V617F in mouse bone marrow by retroviral transduction caused a PV-like phenotype without thrombocytosis.
|
18160670 |
2008 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
The recently discovered mutations in patients with CMD (V617F and exon 12 of JAK2 gene, MPL gene), and those identified in hereditary erythrocytosis and in hereditary thrombocytosis have improved our ability to discriminate these conditions.
|
18484677 |
2008 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
However, when a patient presents with isolated thrombocytosis and a positive JAK2 V617F assay, particularly a young woman, the possibility of PV must always be considered because of plasma volume expansion.
|
29516275 |
2018 |
|
Thrombocytosis
|
|
0.100 |
GeneticVariation
|
BEFREE |
His postoperative management included the examination of his peripheral blood as well as bone marrow, which confirmed that the cause of his elevated platelet count was due to JAK2 V617F mutation that is treated by hydroxyurea and aspirin after being discharged from the hospital.
|
18534315 |
2008 |